Erasca Inc. disclosed that it has set terms of its initial public offering, in which the California-based pre-revenue, clinical-stage precision oncology company could be valued up to $1.84 billion. University of California's researcher, Kevan Shokat PhD., is a lead contributor to Erasca's cancer treatment technology.
